Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Shock, Cardiogenic | 22 | 2024 | 711 | 5.280 |
Why?
|
Coronary Care Units | 15 | 2024 | 235 | 2.900 |
Why?
|
Heart Failure | 24 | 2024 | 11879 | 1.910 |
Why?
|
Glucosides | 5 | 2024 | 533 | 1.740 |
Why?
|
Benzhydryl Compounds | 6 | 2024 | 944 | 1.430 |
Why?
|
Cardiology | 10 | 2024 | 1702 | 1.420 |
Why?
|
Myocardial Infarction | 12 | 2023 | 11519 | 1.250 |
Why?
|
Hemorrhage | 7 | 2024 | 3467 | 1.190 |
Why?
|
Cardiopulmonary Resuscitation | 5 | 2022 | 997 | 1.140 |
Why?
|
Foramen Ovale, Patent | 2 | 2019 | 210 | 1.060 |
Why?
|
Hospital Mortality | 20 | 2024 | 5349 | 1.020 |
Why?
|
Tricuspid Valve | 2 | 2019 | 419 | 1.020 |
Why?
|
Heart-Assist Devices | 5 | 2023 | 1292 | 1.000 |
Why?
|
Biphenyl Compounds | 2 | 2021 | 1026 | 0.990 |
Why?
|
Acute Coronary Syndrome | 6 | 2023 | 2194 | 0.980 |
Why?
|
Tricuspid Valve Insufficiency | 2 | 2019 | 362 | 0.950 |
Why?
|
Critical Care | 16 | 2024 | 2715 | 0.930 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2021 | 1065 | 0.890 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2024 | 223 | 0.860 |
Why?
|
Pyridines | 3 | 2021 | 2894 | 0.820 |
Why?
|
Thiazoles | 2 | 2021 | 1542 | 0.820 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2023 | 2145 | 0.800 |
Why?
|
Hemodynamics | 3 | 2023 | 4194 | 0.800 |
Why?
|
Registries | 18 | 2024 | 8375 | 0.790 |
Why?
|
Atrial Fibrillation | 7 | 2023 | 5176 | 0.790 |
Why?
|
Embolism | 3 | 2021 | 401 | 0.780 |
Why?
|
Heart Massage | 2 | 2019 | 32 | 0.730 |
Why?
|
Dyspnea | 2 | 2019 | 1352 | 0.730 |
Why?
|
Intensive Care Units | 12 | 2024 | 3800 | 0.730 |
Why?
|
Calgranulin A | 1 | 2021 | 81 | 0.720 |
Why?
|
Thromboembolism | 4 | 2024 | 1004 | 0.710 |
Why?
|
Calgranulin B | 1 | 2021 | 87 | 0.710 |
Why?
|
Out-of-Hospital Cardiac Arrest | 3 | 2022 | 340 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2024 | 12252 | 0.690 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 1560 | 0.670 |
Why?
|
Stroke Volume | 5 | 2023 | 5622 | 0.670 |
Why?
|
Proteomics | 2 | 2024 | 3912 | 0.640 |
Why?
|
Hospitals, Special | 1 | 2019 | 90 | 0.630 |
Why?
|
P-Selectin | 1 | 2021 | 598 | 0.610 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1751 | 0.610 |
Why?
|
Coronary Restenosis | 1 | 2021 | 396 | 0.600 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2019 | 91 | 0.600 |
Why?
|
Hospitalization | 10 | 2024 | 10840 | 0.590 |
Why?
|
Personnel, Hospital | 1 | 2020 | 285 | 0.590 |
Why?
|
Secondary Prevention | 2 | 2021 | 1474 | 0.550 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 15662 | 0.550 |
Why?
|
Troponin I | 1 | 2021 | 662 | 0.540 |
Why?
|
Risk Assessment | 15 | 2024 | 24315 | 0.530 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 93 | 0.530 |
Why?
|
Cardiovascular System | 1 | 2023 | 841 | 0.510 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1397 | 0.480 |
Why?
|
Consensus | 1 | 2024 | 3212 | 0.470 |
Why?
|
Burnout, Professional | 2 | 2020 | 711 | 0.460 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.450 |
Why?
|
Atherosclerosis | 4 | 2023 | 3433 | 0.440 |
Why?
|
Workload | 1 | 2019 | 849 | 0.440 |
Why?
|
Lactones | 1 | 2016 | 316 | 0.430 |
Why?
|
Stroke | 5 | 2023 | 9755 | 0.420 |
Why?
|
North America | 6 | 2024 | 1289 | 0.410 |
Why?
|
Humans | 89 | 2024 | 768166 | 0.400 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3941 | 0.390 |
Why?
|
Occupational Diseases | 1 | 2020 | 1457 | 0.390 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1483 | 0.380 |
Why?
|
Anticoagulants | 4 | 2024 | 4852 | 0.370 |
Why?
|
Thoracic Surgical Procedures | 1 | 2015 | 350 | 0.370 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1561 | 0.370 |
Why?
|
Education, Medical, Graduate | 4 | 2024 | 2420 | 0.360 |
Why?
|
Healthcare Disparities | 3 | 2024 | 3415 | 0.350 |
Why?
|
Thrombosis | 2 | 2022 | 2957 | 0.350 |
Why?
|
Internship and Residency | 6 | 2024 | 5953 | 0.330 |
Why?
|
Troponin | 3 | 2023 | 535 | 0.330 |
Why?
|
Myocarditis | 1 | 2017 | 802 | 0.330 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.320 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2020 | 242 | 0.320 |
Why?
|
Aged | 28 | 2024 | 171504 | 0.310 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1498 | 0.310 |
Why?
|
Heart Arrest | 4 | 2020 | 1516 | 0.300 |
Why?
|
Middle Aged | 30 | 2024 | 223492 | 0.300 |
Why?
|
Female | 41 | 2024 | 397192 | 0.270 |
Why?
|
Catheters, Indwelling | 2 | 2019 | 436 | 0.270 |
Why?
|
Male | 38 | 2024 | 364719 | 0.260 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2022 | 2763 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3115 | 0.250 |
Why?
|
Risk Factors | 16 | 2024 | 74944 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.250 |
Why?
|
Emergency Medical Services | 2 | 2019 | 1947 | 0.240 |
Why?
|
Critical Illness | 4 | 2022 | 2756 | 0.240 |
Why?
|
Pulmonary Artery | 2 | 2024 | 1946 | 0.240 |
Why?
|
Drug Combinations | 2 | 2021 | 2089 | 0.230 |
Why?
|
Myocardium | 1 | 2017 | 4788 | 0.230 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 1515 | 0.220 |
Why?
|
Patient Admission | 3 | 2019 | 1365 | 0.220 |
Why?
|
Risk | 3 | 2021 | 9613 | 0.220 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2024 | 277 | 0.210 |
Why?
|
Lactates | 1 | 2023 | 401 | 0.210 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2022 | 33 | 0.200 |
Why?
|
Time Factors | 11 | 2024 | 40218 | 0.200 |
Why?
|
Respiration, Artificial | 2 | 2024 | 2726 | 0.200 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 42 | 0.200 |
Why?
|
Arrhythmias, Cardiac | 3 | 2023 | 2258 | 0.190 |
Why?
|
Electric Countershock | 2 | 2019 | 534 | 0.190 |
Why?
|
Lymphopenia | 2 | 2020 | 300 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2024 | 65371 | 0.180 |
Why?
|
Hospital Rapid Response Team | 1 | 2021 | 54 | 0.180 |
Why?
|
Pandemics | 2 | 2020 | 8748 | 0.180 |
Why?
|
Vascular Resistance | 1 | 2023 | 939 | 0.180 |
Why?
|
Chest Wall Oscillation | 1 | 2020 | 16 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 30010 | 0.170 |
Why?
|
Job Satisfaction | 4 | 2015 | 548 | 0.170 |
Why?
|
Patients' Rooms | 1 | 2020 | 63 | 0.170 |
Why?
|
Protective Devices | 1 | 2020 | 72 | 0.170 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10266 | 0.160 |
Why?
|
Platelet Function Tests | 1 | 2021 | 275 | 0.160 |
Why?
|
Peptide Fragments | 5 | 2024 | 5151 | 0.160 |
Why?
|
CD40 Ligand | 1 | 2021 | 528 | 0.160 |
Why?
|
Telecommunications | 1 | 2019 | 79 | 0.160 |
Why?
|
Enalapril | 1 | 2021 | 317 | 0.160 |
Why?
|
Hypotension | 2 | 2024 | 888 | 0.160 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2023 | 2298 | 0.160 |
Why?
|
Ventricular Fibrillation | 3 | 2012 | 537 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10399 | 0.150 |
Why?
|
Hyperkalemia | 1 | 2021 | 234 | 0.150 |
Why?
|
Adamantane | 1 | 2019 | 148 | 0.150 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2019 | 1566 | 0.150 |
Why?
|
Body Fluids | 1 | 2020 | 321 | 0.150 |
Why?
|
Advance Directives | 1 | 2020 | 249 | 0.150 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.150 |
Why?
|
Resuscitation Orders | 1 | 2020 | 271 | 0.150 |
Why?
|
Health Resources | 1 | 2024 | 950 | 0.150 |
Why?
|
Troponin T | 1 | 2023 | 787 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2021 | 542 | 0.150 |
Why?
|
Heart Transplantation | 2 | 2023 | 3301 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.140 |
Why?
|
Dipeptides | 1 | 2019 | 386 | 0.140 |
Why?
|
Aerosols | 1 | 2020 | 634 | 0.140 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.140 |
Why?
|
Hospitals | 3 | 2023 | 3886 | 0.140 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12543 | 0.130 |
Why?
|
Germany | 1 | 2019 | 883 | 0.130 |
Why?
|
Echocardiography | 2 | 2019 | 5047 | 0.130 |
Why?
|
Health Services Misuse | 1 | 2018 | 246 | 0.130 |
Why?
|
Glomerular Filtration Rate | 2 | 2023 | 2227 | 0.130 |
Why?
|
Chest Pain | 1 | 2023 | 1101 | 0.130 |
Why?
|
Epinephrine | 1 | 2019 | 794 | 0.130 |
Why?
|
Double-Blind Method | 3 | 2021 | 12465 | 0.130 |
Why?
|
Student Dropouts | 1 | 2015 | 27 | 0.130 |
Why?
|
Vasoconstrictor Agents | 1 | 2019 | 656 | 0.130 |
Why?
|
Pulmonary Embolism | 2 | 2019 | 2599 | 0.120 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 317 | 0.120 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2019 | 775 | 0.120 |
Why?
|
Renal Insufficiency | 1 | 2021 | 812 | 0.120 |
Why?
|
Leadership | 1 | 2024 | 1397 | 0.120 |
Why?
|
Disease Progression | 3 | 2023 | 13671 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 964 | 0.120 |
Why?
|
Health Status Disparities | 2 | 2024 | 1885 | 0.120 |
Why?
|
Respiratory Insufficiency | 2 | 2020 | 1240 | 0.120 |
Why?
|
Carbon Dioxide | 1 | 2019 | 1148 | 0.120 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 199 | 0.120 |
Why?
|
Electrocardiography | 3 | 2017 | 6412 | 0.110 |
Why?
|
Curriculum | 2 | 2024 | 3782 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3721 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1323 | 0.100 |
Why?
|
Weight Loss | 1 | 2024 | 2721 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15948 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1836 | 0.100 |
Why?
|
Thrombolytic Therapy | 1 | 2021 | 2055 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20227 | 0.100 |
Why?
|
Intubation, Intratracheal | 1 | 2020 | 1359 | 0.100 |
Why?
|
Scoliosis | 1 | 2019 | 793 | 0.100 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 986 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3929 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8054 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2032 | 0.090 |
Why?
|
General Surgery | 2 | 2015 | 1720 | 0.090 |
Why?
|
Platelet Aggregation | 1 | 2014 | 769 | 0.090 |
Why?
|
Comorbidity | 2 | 2023 | 10590 | 0.090 |
Why?
|
Career Choice | 2 | 2015 | 769 | 0.090 |
Why?
|
Foreign Medical Graduates | 1 | 2011 | 76 | 0.090 |
Why?
|
United States | 10 | 2024 | 73039 | 0.090 |
Why?
|
Survivors | 1 | 2021 | 2381 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 117 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2018 | 1567 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2381 | 0.090 |
Why?
|
Pacemaker, Artificial | 1 | 2016 | 828 | 0.090 |
Why?
|
Acute Disease | 1 | 2021 | 7243 | 0.090 |
Why?
|
Terminal Care | 1 | 2022 | 1770 | 0.080 |
Why?
|
Ticlopidine | 1 | 2014 | 730 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2020 | 1807 | 0.080 |
Why?
|
Recovery of Function | 1 | 2019 | 2981 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2784 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3251 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 3109 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2024 | 81762 | 0.080 |
Why?
|
Cardiac Surgical Procedures | 1 | 2024 | 3683 | 0.080 |
Why?
|
Survival Rate | 2 | 2020 | 12840 | 0.080 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.080 |
Why?
|
Radiography | 1 | 2019 | 6983 | 0.070 |
Why?
|
Incidence | 3 | 2023 | 21538 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2337 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14729 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4260 | 0.070 |
Why?
|
Prospective Studies | 7 | 2024 | 54926 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2024 | 22291 | 0.070 |
Why?
|
Health Status | 1 | 2019 | 4091 | 0.070 |
Why?
|
Radioactive Fallout | 1 | 2005 | 7 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2016 | 2080 | 0.070 |
Why?
|
Cohort Studies | 2 | 2019 | 41754 | 0.060 |
Why?
|
Chronic Disease | 1 | 2021 | 9384 | 0.060 |
Why?
|
Nuclear Warfare | 1 | 2005 | 30 | 0.060 |
Why?
|
Defibrillators | 1 | 2005 | 39 | 0.060 |
Why?
|
Adult | 11 | 2023 | 223646 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2024 | 59629 | 0.060 |
Why?
|
Heart Diseases | 1 | 2018 | 2819 | 0.060 |
Why?
|
Biopsy | 1 | 2017 | 6793 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26379 | 0.060 |
Why?
|
Internal Medicine | 1 | 2011 | 1064 | 0.060 |
Why?
|
Minnesota | 1 | 2024 | 339 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3231 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 13014 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2018 | 7951 | 0.050 |
Why?
|
Lecithins | 1 | 2022 | 16 | 0.050 |
Why?
|
Cultural Diversity | 1 | 2007 | 373 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15454 | 0.050 |
Why?
|
Terrorism | 1 | 2005 | 211 | 0.050 |
Why?
|
Sterol O-Acyltransferase | 1 | 2022 | 28 | 0.050 |
Why?
|
Interprofessional Relations | 3 | 2015 | 997 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10101 | 0.050 |
Why?
|
Heart Valves | 1 | 2024 | 284 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8616 | 0.050 |
Why?
|
Patient Discharge | 1 | 2015 | 3479 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5520 | 0.050 |
Why?
|
Diastole | 1 | 2024 | 785 | 0.050 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 240 | 0.040 |
Why?
|
Workplace | 1 | 2007 | 873 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 643 | 0.040 |
Why?
|
Catheters | 1 | 2023 | 427 | 0.040 |
Why?
|
Pneumocystis carinii | 1 | 2020 | 72 | 0.040 |
Why?
|
Disaster Planning | 1 | 2005 | 560 | 0.040 |
Why?
|
Organizational Culture | 2 | 2015 | 513 | 0.040 |
Why?
|
Evaluation Studies as Topic | 2 | 2011 | 1627 | 0.040 |
Why?
|
Coma | 1 | 2022 | 485 | 0.040 |
Why?
|
Interviews as Topic | 3 | 2011 | 2741 | 0.040 |
Why?
|
Lipoproteins, HDL | 1 | 2022 | 682 | 0.040 |
Why?
|
Heparin | 1 | 2024 | 1636 | 0.040 |
Why?
|
Angiography | 1 | 2022 | 1597 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2016 | 39348 | 0.030 |
Why?
|
American Heart Association | 1 | 2021 | 1050 | 0.030 |
Why?
|
Body Mass Index | 2 | 2024 | 13053 | 0.030 |
Why?
|
Students, Medical | 1 | 2009 | 1964 | 0.030 |
Why?
|
Shock | 1 | 2018 | 316 | 0.030 |
Why?
|
Sex Factors | 2 | 2024 | 10632 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2014 | 6568 | 0.030 |
Why?
|
Animals | 3 | 2018 | 169246 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2020 | 2596 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2914 | 0.030 |
Why?
|
Family | 1 | 2023 | 3209 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14783 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 13090 | 0.020 |
Why?
|
Glycopeptides | 1 | 2012 | 225 | 0.020 |
Why?
|
Length of Stay | 1 | 2024 | 6498 | 0.020 |
Why?
|
Self-Help Groups | 1 | 2011 | 194 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2011 | 426 | 0.020 |
Why?
|
Peroxidase | 1 | 2012 | 610 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.020 |
Why?
|
Physicians | 1 | 2007 | 4598 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7064 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2566 | 0.020 |
Why?
|
Social Perception | 1 | 2011 | 434 | 0.020 |
Why?
|
Hospital Administration | 1 | 2011 | 351 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2011 | 643 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1194 | 0.020 |
Why?
|
Communication | 2 | 2011 | 3905 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2011 | 603 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9374 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16726 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3288 | 0.020 |
Why?
|
Motivation | 1 | 2015 | 2020 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2011 | 1820 | 0.010 |
Why?
|
Qualitative Research | 1 | 2015 | 3140 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2011 | 873 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2016 | 3841 | 0.010 |
Why?
|
New England | 1 | 2007 | 1058 | 0.010 |
Why?
|
Random Allocation | 1 | 2008 | 2396 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3857 | 0.010 |
Why?
|
Prejudice | 1 | 2007 | 574 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10760 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2011 | 2403 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 3436 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6316 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2012 | 3858 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2523 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42669 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36535 | 0.010 |
Why?
|
Swine | 1 | 2008 | 5995 | 0.010 |
Why?
|
Biomedical Research | 1 | 2012 | 3463 | 0.010 |
Why?
|
Child | 1 | 2022 | 80917 | 0.010 |
Why?
|
Clinical Competence | 1 | 2009 | 4858 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6211 | 0.010 |
Why?
|